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Background: Recently, carotid angioplasty with stenting (CAS) has evolved as an alternative to carotid endarterectomy
(CEA) for the treatment of carotid occlusive disease. Some concerns have arisen regarding the high cost of stents and
neuroprotection devices, which may inflate the overall procedural costs relative to CEA. We report here a review and
analysis contrasting the clinical outcomes and associated hospital costs incurred for patients treated with either CAS or
CEA.
Methods: Ninety-four consecutive patients with surgically amenable carotid stenosis were offered CAS or CEA. Forty-six
patients elected CAS, and 48 patients underwent CEA. CASwas performedwith the Smart Precise or Acculink stents, and
all procedures included neuroprotection (Filter Wire or Accunet). CEA was performed with patients under general
anesthesia with routine shunting and with Dacron or bovine pericardium patches. Clinical outcomes such as perioperative
mortality, major adverse events (myocardial infarction, stroke, and death), length of stay, and the incidence of
hemodynamic instability were analyzed. Total costs, indirect costs, and direct procedural costs associated with hospital-
ization were also reviewed.
Results: CAS was associated with a shorter length of stay compared with CEA (1.2 vs 2.1 days; P  .02). Differences in
perioperative mortality (0% vs 2%; P  NS), major adverse events (2% vs 10%; P  .36), strokes (2% vs 4%; P  NS),
myocardial infarctions (0% vs 4%; P .49), and hypotension necessitating pressor support (21% vs 18%; PNS) were not
statistically significant. By using cost to charge ratio methodology according to the Medicare report, CAS was associated
with higher total procedural costs ($17,402 vs $12,112; P  .029) and direct costs ($10,522 vs $7227; P  .017). The
differences in indirect costs were not significant ($6879 vs $4885; P  .063).
Conclusions: CAS with neuroprotection was associated with clinical outcomes equivalent to those with CEA but had
higher total hospital costs. These higher costs reflect the addition of expensive devices that have improved the technical
success and the clinical outcomes associated with CAS. (J Vasc Surg 2006;44:270-6.)Strokes are currently the third leading cause of mortal-
ity in the United States.1,2 The efficacy of carotid endarter-
ectomy (CEA) in the management of carotid stenosis has
been proven, and its durability has been tested through
numerous studies, including the North American Symp-
tomatic Carotid Endarterectomy Trial (NASCET),3
Asymptomatic Carotid Artery Stenosis (ACAS),4 European
Carotid Surgery Trial,5 and Asymptomatic Carotid Surgery
Trial6 studies. The North American Symptomatic Carotid
Endarterectomy Trial (NASCET)3 and European Carotid
Surgery Trial5 studies both demonstrated an absolute risk
reduction in subsequent stroke after CEA for patients with
symptomatic carotid lesions. Additional studies, such as the
Asymptomatic Carotid Artery Stenosis (ACAS) study,
demonstrated a similar absolute risk reduction in asymp-
tomatic patients.
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270The early reported experiences with carotid angioplasty
were less promising. Angioplasty alone, when compared
with CEA, was associated with unacceptably high rates of
stroke and death.7 However, several refinements in tech-
nique, such as the addition of self-expanding nitinol stents,
and distal embolic protection devices have yielded satisfac-
tory results. The data from the SAPPHIRE trial8 and the
recently updated Carotid and Vertebral Artery Translumi-
nal Angioplasty Study trial9 have demonstrated clinical
outcomes at least not inferior to those reported for CEA.
The debate continues as to the clinical equipoise of carotid
angioplasty with stenting (CAS) compared with CEA.
Our objective was to report a single-center, non–
industry-supported experience with CAS and CEA. The
total number of patients reported here is 94. The intent of
our investigation was to evaluate and compare the clinical
outcomes and the relative costs of CEA and CAS.
MATERIALS AND METHODS
All potential candidates for carotid artery reconstruc-
tion were offered either CEA or CAS. The initial process of
patient selection included careful education about the risks
and benefits associated with each procedure—particularly
the results of recent trials evaluating CAS for high-risk
patients. The decision to undertake CAS or CEA was made
on the basis of patient preference and overall evaluation by
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criteria for CEA. These included prior neck radiation and
high cervical lesions not accessible by CEA. No specific
exclusion criteria were noted for CAS. Thus, this was not a
randomized trial. This article constitutes our total, consec-
utive experience with patients from a single institution
undergoing CAS (n  46) compared with similar patients
undergoing CEA (n  48) from November 2003 to De-
cember 2005. Criteria for acceptance of patients for CAS
and CEA included an internal carotid artery stenosis of 80%
or greater for asymptomatic patients and 50% or greater
stenosis for symptomatic patients as measured by duplex
ultrasonography. No conflicts of interest were identified
before the initiation of this study. This project was ap-
proved by the institutional review board at our institution.
Coronary artery disease was assessed before CEA and
CAS by reviewing patient history for prior symptoms of
angina, prior myocardial infarction (MI), prior coronary
angioplasty, and prior coronary artery bypass grafting. Rou-
tine preoperative testing for cardiac status included an
electrocardiogram. Any irregularities or substantial cardiac
history prompted a cardiology consultation, with echocar-
diograms and nuclear stress testing as indicated. Postoper-
ative cardiac testing was performed only in patients with
symptoms (such as chest pain, shortness of breath, hypo-
tension, bradycardia, and mental status changes). Routine
evaluation in these cases included an electrocardiogram and
cardiac enzymes. Any irregularities prompted cardiology
consultation with other diagnostics as necessary.
Briefly, the conduct of CAS followed a standard proto-
col. All patients were pretreated with clopidogrel (Plavix,
Sanofi Aventis, Paris, France) and acetylsalicylic acid (aspi-
rin) for 5 days before the procedure. CAS was performed
with patients under conscious sedation in the angio suite.
CAS was performed by using the Smart Precise (Cordis Inc,
Miami Lakes, FL) or Acculink (Guidant Inc, Indianapolis,
IN) stents, and all procedures used either the Filter Wire
(Boston Scientific Inc, Natuck, MA) or Accunet (Guidant
Inc) cerebral protection device. After placement of the
cerebral protection device, patients underwent predilata-
tion of the carotid stenosis with a 4-mm balloon. Postdila-
tion to between 5 and 5.5 mm was performed on all
patients. All patients received 0.5 mg of atropine before
balloon angioplasty to minimize bradycardia. Additionally,
after stent deployment, all patients received an additional
0.5 mg of atropine before final stent dilatation. After the
procedure, patients were maintained on clopidogrel for 6
weeks.
CEA was performed in the operating room with pa-
tients under general anesthesia. All patients had routine
shunt placement. All CEAs were closed by using either a
Dacron (DuPont, Wilmington, Del) patch or a bovine
pericardium patch. Patients received intraprocedural hepa-
rin 100 U/kg immediately before shunt placement. In
addition, all patients initiated therapy with aspirin at least 7
days before surgery and were continued on this medication
indefinitely after surgery.Both CAS and CEA patients were observed overnight
in our intensive care unit (ICU) with frequent neurovascu-
lar examinations (every hour). Our facility lacks a neurovas-
cular stepdown unit. As such, our patients were housed as
boarders in the ICU for neurovascular monitoring. Patients
without complications were discharged the next day from
the ICU.
Patient data were collected retrospectively, including
patient characteristics, patient outcomes, and costs related
to the procedures. Clinical outcomes such as technical
success (defined as completion of the procedure with a
residual stenosis 30% of the luminal diameter),
procedure-related mortality (mortality occurring directly
related to or within 30 days of the procedure), major
adverse events (the combined rate of mortality, MI, and
stroke within 30 days of the procedure), and rates of
perioperative MIs were assessed. In addition, the length of
the procedure-related stay, the length of the ICU stay, and
the incidence of hypotension necessitating pressor agent
support were also analyzed.
Cost data for each individual procedure were obtained
from our financial services department. All costs were nor-
malized to 2005 dollars based on the consumer price index.
To minimize the disparity between hospital charges and
subsequent reimbursement from third-party payers, Medi-
care cost to charge ratio methodology10 was used to deter-
mine adjusted total costs (total costs associated with the
procedures and admissions), direct costs (that is, costs
directly associated with the procedures and admission, such
as materials and room charges), and indirect costs (that is,
costs not directly related to the procedures, such as admin-
istrative costs, meals, and parking). These costs reflected
the actual services received by our patients. Each patient
care–related charge was grouped into a major resource
department (such as pharmacy, radiology, or surgical sup-
ply). The total resources used per department were then
adjusted by using a ratio based on Medicare Part A and B
payment schedules. The resultant cost data reflect the indi-
vidual resource utilization per patient per hospital admis-
sion. In this way, our cost data are more generalizable to
other institutions.
A specific cost breakdown was also performed to deter-
mine the source of any cost disparities. The specific catego-
ries we studied were room and board–associated costs,
surgical vs angiography supply costs, general radiology
costs, operating room time costs, laboratory study costs,
recovery room–related costs, ICU-related costs, pharmacy
costs, and other patient-related costs. Room and board
costs were defined as costs associated with utilization of
patient beds (ICU and surgical ward beds). Surgical vs
angiography suite supply costs reflected supplies used for
interventions (such as Dacron patches for CEA and stents
and neuroprotection devices for CAS). General radiology
costs reflected costs for studies required during routine
patient care not directly related to the procedures (such as
postoperative carotid duplex scans and chest radiographs).
Operating room costs reflected resource utilization of op-
erating room time. Laboratory study costs reflected various
9%
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chemistries or coagulation panels). Recovery room–related
costs reflected services rendered after the procedure for
monitoring and patient care. ICU-related costs reflected
supplies used for ICU care (cardiac monitor, pulmonary
artery catheters, and so on). Pharmacy costs entailed re-
source utilization for all drugs administered during patient
admissions. Finally, other patient care–related costs were
defined as ancillary services (such as physical therapy or
respiratory therapy).
Our CAS and CEA patient data were analyzed and
compared by using an unpaired t test and the Welch t test
where appropriate. Parameters with significant P values
(.05) were determined to be associated with a clinically
significant effect on outcomes. GraphPad InStat 3 (Graph-
Pad Software, Inc, San Diego, Calif) statistical software was
used to analyze the data in this study.
RESULTS
The preprocedure patient characteristics in our CEA
arm (n  48) were similar to those in our CAS patients (n
 46). The mean age in the CEA group was 73 years, vs 69
years in the CAS group (PNS). The average peak systolic
duplex velocity was 321 cm/s in the CEA group vs 335
cm/s in the CAS group (P  .61). Our CEA group had
more symptomatic lesions (38% vs 22%) than the CAS
group (P  .05). Both groups also had a nearly even sex
Table I. Patient characteristics
Variable
Carotid enda
(n
Mean age (y)
Peak systolic velocity (cm/s)
Symptomatic lesions 3
% Male 5
Tobacco abuse 6
Diabetes mellitus 2
Hypertension 9
Coronary artery disease 5
Prior coronary artery bypass graft 3
Chronic obstructive pulmonary disease 1
Table II. Comparison to SAPPHIRE patients
Variable
CEA patients
(n  48)
SAP
Mean age (y) 73
% Male 56%
Diabetes mellitus 21%
Hypertension 96%
Coronary artery disease 56%
COPD 19%
Prior CABG 33%
Symptomatic lesions 38%
CEA,Carotid endarterectomy;CAS, carotid angioplasty with stenting;COPdistribution (56% male vs 50% male in the CEA and CASgroups, respectively; P .67). Diabetes wasmore prevalent
in the CAS than in the CEA group (41% vs 21%; P  .04).
In addition, coronary artery disease was also more prevalent
in the CAS vs the CEA group (76% vs 56%; P  .05). The
remainder of the patient characteristics of our CEA and
CAS groups are summarized in Table I. These patient
characteristics were also reproduced and compared with the
corresponding SAPPHIRE trial patient characteristics in
Table II.
Technical success was achieved in all CEA and CAS
patients. There was only one procedure-related mortality in
the CEA group, and there was none in the CAS group (2%
vs 0%; P  NS). This mortality was attributed to a fatal MI
on the second postoperative day. The rate of major adverse
events was 10% in the CEA group and 2% in the CAS group
(P  .36). There were two strokes in the CEA group, and
there was one stroke in the CAS group (P  NS). In our
CEA group, one stroke occurred immediately after surgery
and was nonhemispheric. This patient has symptoms of
contralateral arm weakness that continued for several weeks
after surgery. No changes were noted on computed tomo-
graphic scan or magnetic resonance imaging of the head.
The second stroke in our CEA group occurred 7 days after
surgery. A computed tomographic scan demonstrated a
minor infarct in the territory of the ipsilateral middle cere-
bral artery (MCA). This patient had symptoms of aphasia
and weakness of the contralateral hand. These deficits were
tomy group
)
Carotid angioplasty
and stenting group
(n  46) P value
69 NS
335 .61
22% .05
50% .67
48% .21
41% .04
93% .67
76% .05
30% .82
20% NS
RE CEA
167)
CAS patients
(n  46)
SAPPHIRE CAS
(n  167)
.6 69 72.5
7% 50% 67%
.5% 41% 25.3%
.1% 93% 85.5%
.5% 76% 85.8%
.8% 20% 17%
.8% 30% 43.4%
.7% 22% 29.9%
onic obstructive pulmonary disease;CABG, coronary artery bypass grafting.rterec
 48
73
321
8%
6%
3%
1%
6%
6%
3%PHI
(n 
72
6
27
85
75
13
30
27noted to be present up to 12 months of follow-up. One
21
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vention. The patient presented with somnolence and an
expressive aphasia several hours after CAS. A computed
tomographic scan was negative, but a magnetic resonance
image demonstrated a minor infarct in the ipsilateral MCA
territory. These symptoms completely resolved within 7
days of the procedure. There were two MIs in the CEA
group, and there was one in the CAS group (P  .49).
Although the one fatality in the CEA group occurred as a
consequence of an MI, the mortality and MI were counted
as two major adverse events by the criteria used to define
this combined measure of adverse clinical outcomes. The
fatal MI was diagnosed by autopsy, and the other adverse
events were diagnosed by electrocardiogram changes and
elevated cardiac enzymes. These two cardiac events repre-
sent subendocardial infarcts. The average length of stay was
longer in the surgical vs the CAS group (2.1 vs 1.2 days; P
 .02). The duration of ICU admission was 0.8 days in the
CEA group and 1.1 days in the CAS group (P  .15).
Hypotension necessitating pressor support occurred in 18%
of the CAS group vs 21% in the CEA group, but this was
not statistically significant (PNS). These results are listed
in Table III.
Our analysis of the costs associated with these two
procedures produced the following results. The mean total
cost associated with CEAwas $12,112.98, whereas the cost
associated with CAS was $17,402.40. This difference was
statistically significant (P  .03). The mean direct cost for
CEA was $7227.18, compared with $10,522.56 for CAS
(P  .02). A difference was also noted for a mean indirect
cost for CEA of $4884.98 and $6879.84 for CAS, but this
difference did not reach statistical significance (P  .06).
These data are summarized in Table IV.
A specific cost breakdown was also performed to deter-
Table III. Clinical outcomes
Variable
Carotid en
(
Technical success of procedure
Procedure-related mortality 2%
Major adverse events 10%
Strokes 4%
Myocardial infarction (MI) 4%
Length of stay (d)
Intensive care unit length of admission (d)
Hypotension necessitating pressor support
Table IV. Cost data
Variable
Carotid
endarterectomy
group (n  48)
Angioplasty and
stenting group
(n  46) P value
Total costs $12,112.28 $17,402.40 .030
Direct costs $ 7227.18 $10,522.56 .017
Indirect costs $ 4884.98 $ 6879.84 .063mine the source of these cost disparities. Specifically, weanalyzed room and board, surgical vs angiography supply,
general radiology, operating room time, laboratory study,
recovery room–related, ICU-related, pharmacy, and other
patient-related costs. These results are summarized in Table
V. Compared with CAS, CEA was more expensive with
respect to laboratory, postanesthetic care unit, pharmacy,
and other patient care–related costs. Differences in room
and board, general radiology, operating room time, and
ICU care costs were not statistically significant. However, a
marked difference was noted between the costs of surgical
supplies as compared with angiography suite supply costs
($1953 vs $15,407; P  .001).
DISCUSSION
This study demonstrated that there were no significant
differences in the rates of technical success, 30-day com-
bined all-cause mortality and stroke rates, rates of MIs,
lengths of ICU admission, or the incidence of clinically
significant hypotension. However, a statistically significant
reduction in length of stay was noted for CAS vs CEA (1.2
vs 2.1 days); this is consistent with other reports.11-13
These clinical parameters indicate that CAS is not inferior
to CEA.
Recently, the results of several studies have suggested
the equivalency of carotid angioplasty and CEA as the
technique of carotid angioplasty has been refined.9 The
outcomes of the SAPPHIRE trial reveal a statistical benefit
rectomy group
48)
Carotid angioplasty
and stenting group
(n  46) P value
% 100% NS
eath) 0% NS
vents) 2% (1 event) .36
rokes) 2% (1 stroke) NS
Is) 0% .49
1.2 .02
1.1 .15
% 18% NS
Table V. Cost breakdown
Individual cost
CEA group
(n  48)
CAS group
(n  46)
P
value
Room and board $2351 $ 1403 .07
Surgical vs angio suite supplies $1953 $15,407 .001
General radiology costs $ 263 $ 107 .09
OR time costs $2335 $ 0 NS
Laboratory costs $1815 $ 195 .001
PACU costs $ 403 $ 110 .001
ICU care costs $ 124 $ 27 .17
Pharmacy costs $ 957 $ 226 .001
Other care-related costs $ 850 $ 222 .02
CEA, Carotid endarterectomy; CAS, carotid angioplasty with stenting; OR,
operating room; NS, not significant; PACU, postanesthetic care unit; ICU,
intensive care unit.darte
n 
100
(1 d
(5 e
(2 st
(2 M
2.1
0.8in the major adverse event rate favoring CAS (5.8%) when
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have describedmuch lower rates of morbidity andmortality
when comparing their own experience with CEA in high-
risk patients.14 The results of the Carotid Revascularization
Endarterectomy vs Stenting Trial (CREST)15 and Stent-
Supported Percutaneous Angioplasty of the Carotid Artery
vs Endarterectomy16 trials, when they are completed, will
provide more data regarding the clinical outcomes associ-
ated with these interventions.
Some of the clinical outcomes reported here are not
what was initially expected. Postprocedure hypotension
necessitating pressor support was high in both our CEA
and CAS cohorts. Literature reports of postprocedure hy-
potension in CAS patients range from 10% to 51%.17-19
Similar hypotension occurs at a much lesser rate in CEA
patients, reported from 3% to 10%.18,19 We noted that 21%
of our CEA patients and 18% of our CAS patients experi-
enced hypotension necessitating transient pressor support.
This complication could certainly increase both adverse
events and costs. However, no statistically significant dif-
ference was noted between our two treatment groups.
Another potential confounding variable pertains to the
length of ICU admission. All our CAS and CEA patients
were admitted to the ICU as boarders for neurovascular
monitoring. In essence, this practice pattern at our institu-
tion might cause an overestimation of care provided and of
resource utilization for these admissions.
Length of stay was significantly longer in our CEA
group compared with our CAS group (2.1 vs 1.2 days).
Our current practice guidelines include a next-day dis-
charge for both CEA and CAS patients. Most surgeons
discharge CEA patients the day after surgery, and some
have even advocated discharge on the same day for uncom-
plicated cases. However, our experience included some
complicated CEA cases with a longer length of stay.
Analysis of our patient characteristics also demon-
strated some statistically significant differences that might
represent confounding variables. More patients in our CEA
cohort had symptomatic lesions before the procedure, and
more CAS patients had comorbid coronary artery disease
and diabetes mellitus. The higher incidence of these co-
morbid states before surgery could skew results in each
respective group toward adverse outcomes. However, we
do not believe that a selection bias occurred to favor
healthier individuals in either cohort.
In contrast to the apparently equivalent clinical out-
comes measured, the cost analysis of these data indicated
substantially higher total and direct costs associated with
CAS compared with CEA. These findings are similar to
those reported by Gray et al.20 CAS was far more costly
with respect to procedure-related materials. In particular,
the angio suite costs of $15,407 for stents, neuroprotection
devices, and other catheters far outweighed the supply costs
for CEA ($1953). Specifically, the carotid stent and neuro-
protection devices add approximately $3800 to $4000 to
the procedure. Because there are currently only two ap-
proved stents and three neuroprotection devices for this
specific indication, it may be assumed that these high costsmay diminish in the future once competitive devices are
approved.
To our knowledge, only a few studies have investigated
the cost differential between CEA and CAS.21 Some of
these studies are in concert with our findings and indicate a
higher cost associated with CAS.21,22 In contrast, two
additional studies did not demonstrate a statistically signif-
icant difference in cost, but these studies did not include
the routine use of distal embolic protection devices.23,24
One study, by Gray et al,20 actually indicated lower costs
associated with CAS vs CEA.20 However, this study also
did not include the routine use of neuroprotection devices.
Currently, to our knowledge, this is the only study to
analyze cost data associated with CAS and CEA to reflect
the changes brought forth by the Center for Medicare and
Medical Services guidelines.25
Some of the results of our cost analysis are also subject
to confounding variables. A significant difference in clinical
laboratory costs ($1815 for CEA and $195 for CAS) was
noted in our analysis. The longer length of stay evident in
our CEA group could account for greater overall resource
utilization. We also noted that no cost was incurred for
operating room time in our CAS group. This resource
utilization was included in total angio suite supply costs,
because angio suite time represents a different level of
resource utilization (in terms of equipment, personnel, and
operating room scheduling). Differences in laboratory
costs did reach statistical significance between our two
treatment groups ($1815 for CEA vs $195 for CAS; P 
.001). No routine laboratory tests were indicated for either
treatment arm, and the origin of these increased costs
remains unclear.
There are several limitations inherent to this study. First
and foremost, the limited number of patients may bring the
power of this study into question. However, the purpose of
this study was to provide an initial single-institutional ex-
perience with CEA compared with CAS. Few, if any, arti-
cles have been published, to our knowledge, to compare
and contrast the clinical outcomes and costs associated with
these two modalities. The results of our study are meant to
stimulate subsequent trials to address this issue of clinical
outcome and cost.
Another limitation of this study is the fact that these
data were retrospectively collected. Many inherent biases
are prevalent in this type of study, regardless of careful
analysis by the investigators. However, CAS with neuro-
protection is a relatively new technique, and the results of
our analysis may still provide some utility to evaluate this
new modality. In addition, this study comprised a consec-
utive experience with CAS at a single institution. Some
groups have indicated that a steep learning curve is inherent
to CAS. We did not exclude early cases, because any clinical
practice must accept early, and possibly suboptimal, results
with CAS.
Any cost analysis is limited by the variable nature of
financial data. Although we attempted to normalize our
data by adjusting our cost to 2005 dollars and used Medi-
care cost estimates, it is difficult to fully realize the absolute
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patients with complications in this study. Although some
might argue that differences in the severity of complications
might skew cost data (such as length of stay, ICU costs, and
pharmacy costs), these differences in cost reflect the reality
of this patient population.
A detailed analysis of the specific costs itemized per
patient with respect to the surgical supply and angio suite
supply cost departments has confirmed the substantial cost
differential we observed. We can justify our data on the
basis of two observations. The first observation was that the
interventional procedure was not a bundled procedure.
Each guidewire, stent (in some cases, multiple stents),
neuroprotection device, angioplasty balloon, sheath, an-
giogram, and catheter used was a separate cost. In compar-
ison, CEA was performed by using bundled costs. Al-
though this unbundled cost coding practice may inflate
resource utilization, this practice will likely change in the
near future, and this may appropriately reduce some of the
cost associated with CAS. A second major difference be-
tween CAS and CEA regards the disposable nature of CAS
supplies, in comparison to the reusable nature of most
vascular surgical sets. Every guidewire, neuroprotection
device, angioplasty balloon, and so on was discarded after
each case. This represents a significant consumable utiliza-
tion of resources. To put this into perspective, if every
surgical instrument used during CEA were discarded in-
stead of reused, the surgical supply costs would be astro-
nomically higher.
The findings of our internal analysis have demon-
strated that CAS is not inferior to CEA in terms of
clinical outcomes. In addition, the average length of
admission for our CAS group is shorter than for the
surgical group. However, a cost savings from shorter
admissions is dwarfed by the overwhelmingly high costs
associated with catheter-based interventions. Therefore,
the routine use of CAS as an alternative to supplant CEA
cannot be justified on the basis of clinical outcomes and
cost savings. At present, a selective utilization of CAS
may be justified in patients unsuitable for CEA. The
limiting factor for CAS concerns prohibitive cost differ-
ences and not patient outcomes. However, the promise
of further technological innovations (such as drug-elut-
ing stents) may further enhance the clinical outcomes
associated with this alternative approach.
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